Wird geladen...
Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
PURPOSE: Netarsudil is a Rho kinase/norepinephrine transporter inhibitor currently in phase 3 clinical development for glaucoma treatment. We investigated the effects of its active metabolite, netarsudil-M1, on outflow facility (C), outflow hydrodynamics, and morphology of the conventional outflow p...
Gespeichert in:
| Veröffentlicht in: | Invest Ophthalmol Vis Sci |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
The Association for Research in Vision and Ophthalmology
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5114035/ https://ncbi.nlm.nih.gov/pubmed/27842161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1167/iovs.16-20189 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|